Top

International Journal of Clinical Oncology

Published in:

01-10-2018 | Original Article

Low expression of CD40L in tumor-free lymph node of oral cavity cancer related with poor prognosis

Authors: Yoon Chan Rah, Jae-Cheul Ahn, Eun-Hui Jeon, Hyojin Kim, Jin Ho Paik, Woo-Jin Jeong, Soon-Young Kwon, Soon-Hyun Ahn

Published in: International Journal of Clinical Oncology | Issue 5/2018

Abstract

Background

Recently, the genetic alterations associated with tumor progression and impaired host immunity against transformed cells draw increased attention. Here, we characterized the differential gene expression patterns and protein expression in tumor-free lymph node from recurrent and non-recurrent tumors to identify independent prognostic markers for oral squamous cell carcinoma (OSCC).

Methods

A cDNA microarray analysis was performed to identify the differentially expressed genes in regional tumor-free lymph nodes from OSCC patients with and without recurrence. Then, the protein expression of the selected genes was analyzed by immunohistochemistry in 60 OSCC patients to determine their association with survival.

Results

Widespread down-regulation of genes involved in antigen processing and recognition in lymph nodes was a distinctive feature. In univariate Kaplan–Meier analysis, lower expression of CD40L and CD80 in tumor-free lymph nodes was significantly correlated with poorer survival. In multivariate Cox regression analysis, CD40L was identified as an independent prognostic marker of disease-free survival.

Conclusion

Our data indicate that impaired host immunity (decreased CD40L expression) along with the TNM staging might be an important factor determining the prognosis of OSCC.

Available only for authorised users

Warnakulasuriya S (2009) Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 45(4–5):309–316CrossRefPubMed

Chen YJ, Lin SC, Kao T et al (2004) Genome-wide profiling of oral squamous cell carcinoma. J Pathol 204(3):326–332CrossRefPubMed

Marcus B, Arenberg D, Lee J et al (2004) Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma. Cancer 101(12):2779–2787CrossRefPubMed

Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723CrossRefPubMedPubMedCentral

Wherry EJ (2011) T cell exhaustion. Nat Immunol 12(6):492–499CrossRefPubMed

Hathaway B, Landsittel DP, Gooding W et al (2005) Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. Laryngoscope 115(3):522–527CrossRefPubMed

Hoffmann TK, Bier H, Whiteside TL (2004) Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 53(12):1055–1067CrossRefPubMed

Whiteside TL (2005) Immunobiology of head and neck cancer. Cancer Metastasis Rev 24(1):95–105CrossRefPubMed

Hoffmann TK, Dworacki G, Tsukihiro T et al (2002) Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8(8):2553–2562PubMed

10.

Alhamarneh O, Agada F, Madden L et al (2011) Serum IL10 and circulating CD4(+) CD25(high) regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma. Head Neck 33(3):415–423PubMed

11.

Allred DC, Harvey JM, Berardo M et al (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11(2):155–168PubMed

12.

Germain RN (1994) MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76(2):287–299CrossRefPubMed

13.

Crespo J, Sun H, Welling TH et al (2013) T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol 25(2):214–221CrossRefPubMedPubMedCentral

14.

Dong H, Chen L (2003) B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med 81(5):281–287CrossRefPubMed

15.

Korniluk A, Kemona H, Dymicka-Piekarska V (2014) Multifunctional CD40L: pro- and anti-neoplastic activity. Tumour Biol 35(10):9447–9457CrossRefPubMedPubMedCentral

16.

Bereznaya NM, Chekhun VF (2007) Expression of CD40 and CD40L on tumor cells: the role of their interaction and new approach to immunotherapy. Exp Oncol 29(1):2–12PubMed

17.

Tong AW, Stone MJ (2003) Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 10(1):1–13CrossRefPubMed

18.

Brunekreeft KL, Strohm C, Gooden MJ et al (2014) Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death. Mol Cancer 13:85CrossRefPubMedPubMedCentral

19.

Tomihara K, Kato K, Masuta Y et al (2008) Gene transfer of CD40-ligand to dendritic cells stimulates interferon-gamma production to induce growth arrest and apoptosis of tumor cells. Gene Ther 15(3):203–213CrossRefPubMed

20.

Tomihara K, Kato K, Masuta Y et al (2007) Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells. Int J Cancer 120(7):1491–1498CrossRefPubMed

21.

Solomon DA, Kim T, Diaz-Martinez LA et al (2011) Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 333(6045):1039–1043CrossRefPubMedPubMedCentral

22.

Solomon DA, Kim JS, Bondaruk J et al (2013) Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 45(12):1428–1430CrossRefPubMedPubMedCentral

23.

Evers L, Perez-Mancera PA, Lenkiewicz E et al (2014) STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. Genome Med 6(1):9CrossRefPubMedPubMedCentral

24.

You YJ, Chen YP, Zheng XX et al (2012) Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients. Cancer Lett 315(2):138–144CrossRefPubMed

25.

Hou J, Deng L, Zhuo H et al (2015) PTPROt maintains T cell immunity in the microenvironment of hepatocellular carcinoma. J Mol Cell Biol 7(4):338–350CrossRefPubMed

26.

Dunn TA, Fedor H, Issacs WB, et al (2009) Genome wide expression analysis of recently processed formalin-fixed, paraffin embedded human prostate tissues. Prostate 69:214–218CrossRefPubMedPubMedCentral

27.

Coudry RA, Meireles SI, Stoyanova R et al (2007) Successful application of microarray technology to micodissected formalin-fixed, paraffin embedded tissue. J Mol Diagn 9:70–79CrossRefPubMedPubMedCentral

28.

Fedorowicz G, Guerrero S, Wu TD et al (2009) Microarray analysis of RNA extracted from formalin-fixed, paraffin embedded and matched fresh-frozen ovarian adenocarcinomas. BMC Med Genom 2:23–34CrossRef

Title: Low expression of CD40L in tumor-free lymph node of oral cavity cancer related with poor prognosis
Authors: Yoon Chan Rah
Jae-Cheul Ahn
Eun-Hui Jeon
Hyojin Kim
Jin Ho Paik
Woo-Jin Jeong
Soon-Young Kwon
Soon-Hyun Ahn
Publication date: 01-10-2018
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 5/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1294-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2018

Influence of incomplete neoadjuvant chemotherapy on esophageal carcinoma

Early intervention using high-precision radiotherapy preserved visual function for five consecutive patients with optic nerve sheath meningioma

Development and external validation of a nomogram to predict high-grade papillary bladder cancer before first-time transurethral resection of the bladder tumor

Analysis of unexplained carcinoembryonic antigen elevation after curative treatment of locally advanced rectal cancer

Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

Treatment outcomes of patients with spinal metastases derived from hepatocellular carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer